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ABSTRACT 
Diabetes and atherosclerosis are two chronic pathologies which 
prevalence is constantly growing worldwide, leading to disability and 
life-threatening complications. Since their consequences represent major 
causes of mortality and morbidity in developed countries, the 
identification and characterisation of new potential biomarkers may 
contribute to revealing the underlying mechanisms of pathology onset 
and progression, and to improving the diagnostic methodologies and the 
therapeutic approaches used for the treatment of these pathological 
conditions. 
 
A method recently developed was applied to urine from type 1 and type 
2 diabetes patients and healthy controls for quantitation and structural 
characterisation of Urinary Trypsin Inhibitor (UTI), evidencing higher 
levels of this proteoglycan in both classes of patients with respect to 
controls. Furthermore, mass spectrometry (MS) analysis revealed 
oxidative post-translational modifications, which may affect UTI 
localization, function and pathophysiological activity 
 
Lipoproteomics of purified plasma VLDL, LDL and HDL fractions from 
both patients undergoing carotid endarterectomy and healthy controls 
was performed by 2-DE coupled with MS, allowing the identification of 
Acute Phase-SAA as a potential biomarker of advanced atherosclerotic 
lesions. A role of LDL as Acute Phase-SAA carrier into the 
subendothelial space of arteries was also suggested. 
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INTRODUCTION 
Diabetes and atherosclerosis are two chronic pathologies that are 
strongly correlated with higher rates of morbidity and mortality in 
Western countries, with a prevalence that is constantly growing 
worldwide, even in low- and middle-income countries. 
Since the consequences of these diseases can lead to disabling and life-
threatening complications, it might be of great interest to identify and 
characterize potential biomarkers, which may be useful to monitor these 
pathological conditions, as well as may contribute to revealing the 
underlying mechanisms of pathology onset and progression, helping in 
the improvement of the diagnostic methodologies and the therapeutic 
approaches used for the treatment of these pathological conditions. 
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CHAPTER 1: Development of a method for urine 
bikunin/urinary trypsin inhibitor (UTI) quantitation 
and structural characterization: Application to type 1 




Diabetes is a chronic disease, consisting either in a lack of insulin 
synthesis or in insulin resistance by target cells, which leads to persistent 
high blood concentration of glucose. Insulin is a hormone, produced by 
β-cells in the islets of Langerhans of pancreas, which main function is 
the regulation of glucose uptake from blood, allowing cells to store it or 
to convert it into energy. Insulin is synthetized as a precursor of 110 
amino acids called preproinsulin, encoded by a single gene located on the 
distal end of the short arm of chromosome 11 [1], and its 24 amino acids 
signal peptide is cleaved thus forming the 86 amino acid long peptide 
called proinsulin. The mature hormone consists in two polypeptide 
chains, the A- and B- chains of 21 and 30 amino acid respectively, linked 
together by two disulphide bonds and is stored as Zn
2+
-stabilized 
hexamers into secretory granules [2]. 
Insulin is fundamental in the regulation of anabolism, inducing the 
uptake of glucose, amino acids and fatty acids into cells, promoting the 
synthesis of glycogen, lipids and proteins, and inhibiting their 
degradation and release into the circulation [3]. 
The metabolic diseases resulting from the defect in insulin secretion or 
action, determine chronic hyperglycemia which early symptoms are 
polyuria, polydipsia, weight loss, sometimes with polyphagia, and 
blurred vision [4]. 
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It is possible to distinguish three main types of diabetes according to the 
mechanisms underlying the dysfunction in carbohydrate metabolism.  
 
Type 1 diabetes, also known as immune-mediated diabetes, is triggered 
by an autoimmune destruction of insulin-producing pancreatic β-cells 
which leads to insufficient production of insulin. The etiology is not 
completely known yet, as diabetic disease is in relation with several 
genetic and environmental factors that are poorly defined so far [4]. The 
onset is typically associated with childhood or adolescence but it can 
affect people of any age, usually leading to compulsory insulin treatment 
to prevent the development of ketoacidosis, as in most cases insulin 
shortage is absolute for type 1 diabetic patients [5]. Type 1 diabetes 
frequency in Italy accounts for 3 to 6% of all diabetic diseases, except for 
Sardinia, in which type 1 diabetes frequency is more than three times 
greater with respect to the mean incidence in the rest of the country and 
the second highest in the world after Finland (up to 45 cases a year / 
100,000) [6]. 
 
Conversely, insulin resistance or its hyposecretion can lead to type 2 
diabetes syndrome, an adult-onset dysfunction which often does not 
require insulin treatment. Obesity, poor diet, physical inactivity and 
family history of diabetes are some of the risk factors related with this 
metabolic disorder although the specific etiology is not known yet. 
Frequently this condition remains undisclosed for years, as 
hyperglycemia develops gradually and it is often difficult to perceive the 
classical symptoms of diabetes [4]. Type 2 diabetes prevalence is greater 
with respect to type 1, as it represents nearly 90% of all cases of diabetes 
in the world. It is particularly worrying that the incidence of type 2 
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diabetes in youth, as well as the obesity rates in adolescence, is rapidly 
increasing [7]. 
 
When insulin resistance occurs during pregnancy, usually around the 24
th
 
week, subsequent high blood glucose levels lead to a condition known as 
gestational diabetes, that habitually resolves with delivery [4, 8]. Women 
affected by this disorder normally need to follow a dietary plan and to do 
physical exercise to control their blood glucose levels, in order to avoid 
consequences for both the mother and her baby. In some cases insulin or 
medical treatment are necessary for managing gestational diabetes and to 
prevent pathologies as macrosomia or preeclampsia, hazardous 
dysfunctions for both new-born and pregnant [8]. 
 
In both type 1 and type 2 diabetes, the resulting hyperglycemia can lead 
to severe long-term damage of different organs, particularly eyes, 
kidneys, nerves and blood vessels. More in detail, complications of 
diabetes include damages to retina with potential loss of vision, 
nephropathy leading to renal failure, peripheral neuropathy with 
prospective foot ulcers, non-traumatic lower limb amputations, 
autonomic neuropathy causing gastrointestinal, genitourinary and sexual 
dysfunction [4]. 
Nonetheless, persistent elevated blood glucose levels are associated with 
a two or three-fold increase risk of cardiovascular disease that represents 
the major cause of mortality in patients with diabetes [9, 10]. Moreover 
diabetic patients are more prone to angina, myocardial infarction, stroke, 
peripheral artery disease, and congestive heart failure, as well as to 
increased risk of cardiovascular complications [8, 10]. Actually, long-
term patients affected by insulin-related dysfunctions are more 
predisposed to cardiovascular diseases, as well as hypertension and 
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abnormalities of lipoprotein metabolism [4]. Additionally, it has been 
reported an association between diabetes and accelerated atherosclerosis 
macrovascular disease regarding blood vessels that supply the heart, 
brain and lower extremities that can lead diabetic patients to higher risk 
of myocardial infarction, stroke and limb amputation [11]. 
The mechanisms underlying these alterations are related with superoxide 
overproduction by the mitochondrial electron-transport chain, which 
results in greater oxidative stress and higher levels of reactive oxygen 
species (ROS) [12]. ROS production is stimulated by intermittent 
hyperglycemia rather than permanent hyperglycemia [9], as supported by 
in vitro [13, 14], in vivo [15] and clinical studies [16], through four main 
pathways: increased polyol pathway flux, increased advanced glycation 
end-product (AGE) formation, activation of protein kinase C (PKC) 
isoforms, and increased hexosamine pathway flux [11]. 
Other mechanisms contributing to vascular damage and higher 
cardiovascular disease risk in patients affected by both type 1 and type 2 
diabetes are dyslipidemia [17], hyperglycemia-related glycated albumin, 
which has been suggested to promote atherosclerosis by impairing 
albumin anti-oxidant activity [18, 19], and hypoglycemia that may 
induce regulatory responses as inflammation, blood coagulation 
abnormality, sympathoadrenal response and endothelial dysfunction or 
increased risk of arrhythmia [20-23]. 
 
Diabetes is a huge and growing problem all over the world, affecting 
about 382 million people in the world, 80% of which living in low- and 
middle-incoming countries. Despite all healthcare policies conducted by 
all countries in the world during the last years, estimates indicate that the 
number of diabetic patients will significantly increase in the next 20 
years [8, 24].  
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Beyond its negative effects on people health, diabetes represents a 
noteworthy threat to global development, as it costs 548 billion dollars in 
health spending [25, 26]. 
 
1.2. BIKUNIN 
Bikunin is a small plasma proteoglycan with Serine Protease inhibitory 
activity. It is composed of a protein moiety as well as two carbohydrate 
chains. The polypeptide portion consists of 147 amino acid residues 
folded in two Kunitz-type domains (7 kDa each) containing three 
disulphide bonds, a connecting peptide as well as an N- and a C-terminal 
moieties of 10-25 amino acid residues [27]. Bikunin is synthetized as a 
352 amino acid residues long precursor protein called α1-
microglobulin/bikunin precursor (AMBP) that, in the secretory vesicles, 
is proteolytically cleaved into the mature form of bikunin and α1-
microglobulin [27, 28], a 25 kDa plasma protein with unclear 
physiological function [29]. A low-sulphated chondroitin sulphate (CS) 
chain, O-linked to the Serine 10, and an oligosaccharide, N-linked to the 
Asparagine 45, are bound to the protein moiety. CS chain is composed 
by 12-18 disaccharide repeating units consisting of N-acetyl 
galactosamine (GalNAc), which may be sulphated either in position C4 
or in C6, and glucuronic acid. The linkage region that connects CS to 
bikunin is composed, as in other types of glycosaminoglycans (GAG), by 
Xyl-Gal-Gal-GlcA. In turn, the N-linked oligosaccharide has a 
biantennary structure typical of glycoproteins [30]. 
Bikunin is synthesized mainly by hepatocytes, even though small 
quantities of coding RNA have been found in stomach, kidney, pancreas 
and intestine too [27]. After being synthesized it is secreted in plasma, 
where about 90-98% occur as a subunit of Inter-alpha-Inhibitor (IαI) 
family molecules, linked via an ester bond between C6 of a non-
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sulphated GalNAc residue of the CS chain and the α-carbon of the C-
terminal amino acid residue of one or two polypeptides [31], called the 
heavy chains, to form IαI and Pre-alpha-Inhibitor (PαI) respectively [32]. 
Due to its inhibitory activity, free bikunin has a half-life of 4-30 minutes 
[27], and it is then rapidly excreted in urine as Urinary Trypsin Inhibitor 
(UTI) [32], which can inhibit various Serine Proteases such as trypsin, 
chymotrypsin, elastase, granzyme K, cathepsin G, acrosin and plasmin 
[27, 33, 34] through its two Kunitz-type domains.  
Despite several studies on bikunin/UTI structure and levels have been 
performed since 1950s, understanding the biological function of bikunin 
deserve further studies [34]. 
 
The molecular mass of the whole bikunin is about 25-26 kDa, being the 
protein core, the CS and the oligosaccharide chains 16 kDa, 7 kDa and 2 
kDa respectively, as reported by various studies and confirmed by 
ultracentrifugation methods [27, 34]. However, because of chondroitin 
sulphate chain extended conformation, bikunin behaves like a globular 
protein of about 67 kDa by gel filtration and has an apparent molecular 
mass of 35-45 kDa by SDS/PAGE [35]. 
 
Bikunin main function is inhibition of proteinases, although many 
studies provided evidences on its activity in stimulating the growth of 
fibroblasts [36], in regulating calcium intracellular levels [37], in 
supporting the formation of the hyaluronan-containing extracellular 
matrix [38] and in inhibiting the formation of kidney stone [39]. When 
associated with IαI bikunin lacks some of its activities, therefore the 
proteolytic cleavage may function as a regulatory mechanism. In fact, 
several research findings indicate that the free proteoglycan is part of the 
inflammatory process as immediate extracellular degradation of IαI 
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occurs during inflammation, releasing bikunin [32]. Following an 
inflammatory stimulus, IαI molecules are recruited from circulation to 
the extravascular sites, where the heavy chains are transferred from CS 
chain to the locally synthesized hyaluronic acid (HA) to form the serum-
derived hyaluronan-associated-protein- (SHAP-) HA complex, which 
supports the formation of extracellular matrix and its stabilization [40].  
Because of its proteinase inhibitory activity, free bikunin is rapidly 
cleared from circulation (approximately 7 minutes) to prevent a 
shutdown of repair and healing processes, by both tissue uptake and 
renal excretion and it is found in urine as Urinary Trypsin Inhibitor 
(UTI) [34, 41]. 
In human, total plasma concentration of bikunin is 4-7 μM, of which 
only 2-10% is in free form, while in urine UTI levels are about 0.03-0.05 
μM, most of which is in free form [27]. UTI levels are usually low in 
healthy individuals but they can increase up to 10 fold in both acute and 
chronic inflammatory diseases [42], bladder carcinoma [43], brain 
contusion [44], disseminated cancers [45], acute hepatitis [46], Fabry's 
disease [47], Crohn’s disease, arthritis, pericarditis, deep vein 
thrombosis, fibromyalgia, asthmatiform bronchitis [48], neoplasia and 
kidney diseases [27]. 
Actually, UTI can be considered a positive acute phase protein useful as 
a marker to easily and rapidly monitor an inflammatory condition [32, 
48]. 
To date, UTI quantification in urine is performed mainly by means of 
either enzyme inhibition or immunological detection [28]. In general, all 
UTI forms are measured together [32], either directly or indirectly. 
Unfortunately, these approaches may be affected by either low 
specificity or sensibility. 
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More in detail, enzyme inhibition methods rely on the addition of both 
known amounts of trypsin and a substrate to the specimen, to measure 
the degree of trypsin inhibition. When the substrate is cleaved by trypsin 
it yields to detectable products [48]; if UTI or other trypsin inhibitors are 
present in the sample, some of the available substrate is not cleaved by 
trypsin and the response is then reduced [32]. Dipstick methods, based 
on enzyme inhibition, are available for the rapid detection and 
quantitation of urinary trypsin inhibitors [49, 50]. Besides allowing easy 
and rapid UTI quantification resulting in colour shift, these methods have 
a detection limit of about 6.25 mg/L, resulting in low sensitivity [28]. 
Furthermore, methods based on enzyme inhibition do not take into 
account normalization for creatinine levels. 
On the other hand, ELISA or western blotting, which both rely on either 
mono- or polyclonal antibodies, are affected by degree and specificity of 
the immunological reaction. More in detail, while ELISA tests do not 
discriminate among free UTI, UTI containing complexes (AMBP, PαI, 
IαI) or UTI fragments [28, 32], absolute and reproducible protein 
quantitation is not possible by means of western blotting analysis. 
 
Since no existing methods for UTI quantitation contemplate 
normalization for creatinine levels, we decided to set up a sensitive 
method for UTI quantitation and its structural characterization, starting 
from low quantities of specimen. Merging classical chromatographic 
methods, already applied by our research group for GAG and 
proteoglycan purification [47, 51-54], with image analysis of SDS-
PAGE profiles, effective for the quantification of micro quantities of 
proteins [55], we were able to directly measure UTI levels and to 
perform its structural characterization by means of mass spectrometry 
(MS).  
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2. AIM OF THE STUDY 
The identification of new biomarkers of diabetes may have a huge 
impact on the great number of people affected by these metabolic 
syndromes. Estimates indicate that in Sardinia about 50,000 people have 
either type 1 or 2 diabetes, making this island the region with the highest 
prevalence in Italy and one of the highest worldwide, together with 
Finland [6]. Taking into account patients along with their families, in 
Sardinia the number of people involved in the diabetic burden raise up to 
250,000 – 300,000, nearly 20% of the entire Sardinian population. 
The aim of this study was the development of an innovative method for 
direct UTI quantitation and structural characterisation in patients affected 
by both type 1 and type 2 diabetes, in relation to kidney function and 
glycemic control. 
To achieve this goal we set up a method consisting in UTI purification 
by anion exchange chromatography followed by SDS-PAGE, 
quantitation by image analysis on SDS-PAGE profiles, and structural 
characterization by both FACE and MS analyses. The MS approach may 
lead to the detection of post translational modifications (PTMs) that 
might affect UTI localization, function and pathophysiological activity. 
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3. MATERIALS AND METHODS 
3.1. SAMPLE COLLECTION 
All experiments were carried out on first morning urine samples from 29 
patients affected by type 1 diabetes (31.76 ± 10.95), 22 patients having 
type 2 diabetes (age 64.05 ± 7.40) and 42 healthy controls (age 38.00 ± 
21.14) matched for age and sex with patients. Urine were collected, 
immediately centrifuged at 5,000 x g for 15 minutes and then stored at  
-20 °C until analysis. Each sample was assessed for creatinine content by 
means of the Jaffè method (Sentinel Diagnostic). Twenty-four hours 
albumin excretion rate (AER) was evaluated by an immunoturbidimetric 
method (Roche Diagnostics). 
UTI purification and quantitation were performed according to a method 
recently developed by our research group [56] with slight modifications. 
 
3.2. ANION EXCHANGE CHROMATOGRAPHY 
UTI was purified starting from a volume of urine corresponding to 5 mg 
of creatinine. Urine samples were loaded onto chromatography columns 
(Econo-Column Chromatography Columns, 0.5 x 20 cm, Bio-Rad 
laboratories) packed with 1 mL of DEAE-Sephacel (GE Healthcare Life 
Sciences), an anion exchange resin, previously equilibrated with a buffer 
containing 0.02 M Tris and 0.15 M NaCl, pH 8.6. The same equilibrating 
buffer was also used to wash away all the by-products and impurities 
contained in urine samples from the column, until absorbance at 280 nm 
was less than 0.05. 
Two gravity feed elution steps were performed, recovering 6 mL each, (I 
step: 0.02 M Tris and 0.45 M LiCl, pH 8.6; II step: 0.02 M Tris and 2 M 
LiCl, pH 8.6) to elute separately CS-containing UTI fraction (I step) or 
free CS in urine (II step) [53]. Concentration and dialysis of the eluted 
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fractions were performed by means of Amicon Ultra-0.5 Centrifugal 
Filter Units (Millipore), according to manufacturer’s instructions. 
 
3.3. CELLULOSE ACETATE ELECTROPHORESIS 
GAG composition was determined by discontinuous electrophoresis 
according to Cappelletti et al. [57]. This method, combined with the 
differential susceptibility of GAGs to precipitation by organic solvents, 
allows optimal and rapid separation of intact GAGs with high resolution 
and sensitivity (10 ng detection limit). GAGs were separated in 0.25 M 
barium acetate buffer, pH 5.0, by three steps. Firstly, Titan III-H zone 
cellulose acetate plate (6.0 x 7.5 cm, Helena BioSciences) was dipped in 
distilled H2O for about 1.5 cm; the plate was immediately blotted 
between filter papers. The opposite end was then immersed in 0.1 M 
barium acetate, pH 5.0, for 5.5 cm, leaving a narrow band (2 – 4 mm 
large) apparently dry between H2O and buffer. The plate was blotted 
again between filter papers, and 5 µl of sample were applied in the 
narrow dry band. The loaded plate was subjected to 5 mA constant 
current for about 6 minutes and then soaked in 0.1 M barium acetate, pH 
5.0, for 2 minutes. In the following step, a 15 mA constant current was 
applied for 14 minutes. The plate was removed once more from the 
chamber and immersed for 2 minutes in 0.1 M barium acetate buffer, pH 
5.0, containing 15% ethanol (v/v). The last electrophoretic step was 
carried out at 12 mA constant current for 17 minutes. Following 
electrophoresis, the plate was stained in 0.1% Blue Alcian (w/v) solution 
for 10 minutes, and destained in 1% acetic acid (v/v). 
Standard GAGs were loaded together with our samples, and their 
different electrophoretic mobility was compared. UTI identification was 
performed by comparing untreated and Chondroitin ABC lyase (Chase-
ABC) treated sample, as further described below. 
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UTI and the different GAG species were expressed as relative 
percentages by densitometric analysis of Alcian blue-stained cellulose 
plates quantitated using Quantity One software, v 4.6.3 (Bio-Rad 
laboratories). 
 
3.4. GAG DEPOLYMERISATION 
The samples were diluted with a 5X buffer, containing 0.5 M ammonium 
acetate, pH 8.0, and then incubated overnight at 37 °C with 0.025 U of 
Chase-ABC (Sigma Aldrich), to completely depolymerize the GAG 
chain into unsaturated disaccharide units. 
Preliminary tests showed that such a quantity of enzyme was effective 
for the complete CS digestion of up to 90 µg of UTI. 
 
3.5. SDS-PAGE 
Chase-treated samples were resolved by means of SDS-PAGE, a 
technique widely used to separate proteins according to their 
electrophoretic mobility. SDS is an anionic detergent that binds to 
polypeptides, giving them identical charge per unit mass, resulting in a 
separation based on protein molecular mass. Furthermore, the presence 
of a reducing agent allows complete proteins linearization by breaking 
disulphide bonds. 
Samples were diluted with 4X Laemmli buffer, containing 250 mM Tris, 
pH 6.8, 8% SDS (w/v), 8% dithiothreitol (DTT) (w/v), 40% glycerol 
(v/v), 0.0008% bromophenol blue, and then subjected to 5 minutes 
boiling step. Protein separation was carried out into 1 mm-thick Tris-
glycine polyacrylamide running gel (15% T, 3% C), using a Mini 
Protean II cell vertical slab electrophoresis apparatus (Bio-Rad 
laboratories). Electrophoresis was performed at 50 V for 15 minutes and 
subsequently at 150 V until the bromophenol blue dye reached the lower 
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limit of the gel. Then gels were fixed in 30% ethanol (v/v), 2% 
phosphoric acid (v/v) for 1 hour, washed twice in 2% phosphoric acid 
(v/v) for 10 minutes, and then equilibrated in 18% ethanol (v/v), 2% 
phosphoric acid (v/v), 15% ammonium sulphate (w/v) for 30 minutes. 
The staining solution, containing 2% Coomassie Brilliant Blue (CBB) G-
250 (w/v), was then added to the solution (0.02% final concentration). 
After 48 hours gels were acquired by means of GS-800 calibrated 
densitometer (Bio-Rad laboratories) at 63 µm resolution, and then 
analysed using Quantity One software, v 4.6.3 (Bio-Rad laboratories) 
[55]. 
 
3.6. ASSAY CALIBRATION 
To assess UTI levels in the samples, we set up a calibration curve, using 
a highly purified UTI fraction. This fraction was obtained from 80 mL of 
a pooled urine sample using a chromatographic column packed with 10 
mL of DEAE-Sephacel resin. 30 mL of eluate were concentrated and 
dialysed with an Amicon Ultra-15 Centrifugal Filter Unit (Millipore). 
Chase ABC treatment and SDS-PAGE were carried out as described 
above. UTI bands were cut from several SDS-PAGE gel lanes, destained 
and dehydrated as reported for MS analysis. UTI was extracted by 
incubating gel pieces in 5 mL of a buffer containing 0.05 M Tris and 2% 
SDS (pH 6.8) for 24 hours at 60 °C. The solution was then concentrated 
using an Amicon Ultra-0.5 Centrifugal Filter Unit (Millipore) and finally 
UTI concentration was determined by means of DC Protein Assay Kit 
(Bio-Rad laboratories), using bovine serum albumin (BSA) as a standard. 
A calibration curve was set up for protein quantitation, by resolving 
different quantities of this highly purified UTI sample (from 0.25 to 4 
µg) by SDS-PAGE.  
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Binding capacity of DEAE-Sephacel resin, both intra- and inter- assay 
Coefficient of Variability (CV), percentage of UTI recovery, method 
sensitivity and test reproducibility were assessed. 
 
3.7. FLUOROTAGGING WITH 2-AMINOACRIDONE 
Depolymerised GAG free reducing ends can be derivatized with 2-
aminoacridone (AMAC) by reductive amination in the presence of 
sodium cyanoborohydride (NaBH3CN) as described by Calabro et al. 
[58]. Briefly, 40 µL of 12.5 mM AMAC solution in glacial acetic 
acid/DMSO (3:17 v/v) were added to Chase ABC-treated sample, 
followed by 15 minutes incubation at room temperature. 40 µL of  
1.25 M NaBH3CN were then added to each sample and mixtures were 
incubated at 37 °C overnight. After derivatization, 20 µL of glycerol 
(20% final concentration) were added to each sample prior to 
electrophoresis. 
 
3.8. FLUOROPHORE ASSISTED CARBOHYDRATE 
ELECTROPHORESIS 
Fluorophore assisted carbohydrate electrophoresis (FACE) allows 
resolving different fluoro-tagged disaccharides species obtained by 
GAGs depolymerisation with specific lyases. It was performed as 
previously described by Karousou et al. [59] in a MiniProtean II cell 
vertical slab gel electrophoresis apparatus (Bio-Rad laboratories). 
Electrophoresis was conducted into 25% T and 7.5% C polyacrylamide 
running gels, previously prepared in 187.5 mM Tris-borate and  
187.5 mM Tris-HCl buffer, pH 8.8. Stacking gels were 5% T and 15% C 
in 0.36 M Tris-HCl buffer, pH 8.8. 5 µL of each sample were loaded in 
each well; a sample of bromophenol blue dye was run in a lane alone to 
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monitor the electrophoresis. Electrophoresis was performed in 0.15 M 
Tris-borate buffer, pH 8.8, at 400 V and 4 °C until the dye was 1.2 mm 
from the bottom of the gel.  
Gels were then acquired by a UV-light box using a CCD camera (Gel 
Doc XR System) and analysed with Quantity One 4.6.3 (Bio-Rad 
laboratories). Identification of sample bands was achieved by comparing 
their electrophoretic mobility with standard ∆-disaccharides, run in the 
same gel. Following Quantity One image analysis, relative percentages 
of different ∆-disaccharide species were calculated. 
To quantify ∆-disaccharides in each sample, a calibration curve was set 
up, loading known quantities ranging from 25 to 800 ng of AMAC-
derivatised ∆-disaccharides obtained by depolymerisation of a highly 
purified UTI sample assayed for hexuronate content, using glucuronic 
acid as a standard, according to the carbazole method by Bitter and Muir 
[60]. 
 
3.9. STATISTICAL ANALYSIS 
Statistical analyses were performed by using Sigma Stat 3 software 
package (Systat software). 
UTI concentration values were reported as median and interquartile 
range, as normality test failed. Mann-Whitney rank sum test was 
performed to evaluate differences among different groups, while 
correlations between UTI levels and age, UTI levels and glycated 
haemoglobin, and UTI levels and micro albuminuria, were assessed by 
Spearman’s correlation. 
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3.10. UTI IDENTIFICATION BY MS ANALYSIS 
After SDS-PAGE separation of pooled urine samples from controls, 
bands corresponding to UTI were excised from gels, finely minced and 
destained with 5 mL solution containing 2.5 mM NH4HCO3, 50% 
acetonitrile (ACN) (v/v), at 60 °C for 2 hours, changing destaining 
solution three times. Gel fragments were dehydrated with 5 mL of pure 
ACN for 15 minutes and dried at room temperature. After reduction with 
10 mM DTT, at 56 °C for 45 minutes, alkylation with 55 mM 
iodoacetamide, at room temperature for 30 minutes, and treatment with 5 
ng/mL trypsin (Promega), obtained peptides were recovered using 50% 
ACN/0.5% formic acid (v/v). 50 µL of the solution containing peptides 
were filtered through 0.22 µm filter, resolved by means of nanoflow RP 
LC and then analysed by a Triple TOF 5600 System (AB SCIEX) 
operating in IDA (information-dependent acquisition) mode. 
Obtained data were processed through MASCOT algorithm (v 2.1.04), 
incorporated in ProteinPilot software (v 4.0.8085; AB SCIEX), against 
the Swiss Prot 2012 human protein database. Variable modifications 
such as methionine oxidation, asparagine and glutamine de-amidation, 
and lysine acetylation were selected. The tolerance for precursor ion and 
MS/MS fragment mass values were set at 25 ppm and 0.3 Da, 
respectively. Trypsin digestion and two possible missed cleavages were 
set up. Only the two top ranked peptide matches were taken into 
consideration for protein identification. 
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4. RESULTS 
In order to perform an accurate quantitation, a calibration curve was set 
up (y = 1.337x – 0.1868, R2 = 0.9943), by loading known quantities of 
highly purified UTI fraction ranging from 0.25 to 4 µg of protein, having 
a linear response between band intensity, expressed as optical density, 
and UTI quantity in the range considered (Figure 1). 
 
 
Figure 1: (A) Calibration curve obtained by image analysis of SDS-PAGE 
profiles of increasing quantities (ranging from 0.25 to 4 µg of protein) of 
purified UTI. (B) UTI bands obtained by SDS-PAGE. OD: optical density. 
 
DEAE-Sephacel binding capacity (about 75 µg / mL of resin), intra- and 
inter-assay CVs (4.93% and 10.63% respectively) and percentage of UTI 
recovery, evaluated at two different concentrations (88.2% and 97.0%), 
as well as method sensitivity (0.5 µg UTI / mg Creatinine) were assessed 
as reported previously [56].  
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UTI identity was confirmed by means of Nano-LC-MS/MS analysis, 
followed by MASCOT search that allowed identification of AMBP 
(UniProtKB/Swiss-Prot: P02760.1), with sequence coverage of 51% and 
a high protein score, as shown in Table 1. This precursor of 352 amino 
acid residues is processed into mature Bikunin and α-1-microglobulin by 
proteolytic cleavage. 
 
Besides confirming bikunin identity, MS analysis allowed the detection 
of post-translational modifications that may represent a potential marker 
of oxidative stress in both type 1 and type 2 diabetic patients. In fact, a 
Proline residue was found to be oxidised in both classes of patients, in 
addition to a dioxidation of a Phenylalanine residue that was detected in 
type 1 diabetes patients (Table 1). 
 
Table 1: MS/MS data, reporting bikunin identification and post-translational 
oxidative modifications. 
 
The two chromatographic fractions (I and II elution), containing either 
UTI or free CS isomers, were analysed for GAG/PG content, UTI 
levels/structure, and chondroitin sulphate structure. 
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GAG composition in purified samples was determined by means of 
cellulose acetate electrophoresis, conducted according to Cappelletti et 
al.[57]. To identify GAGs in both 0.45 M and 2 M LiCl eluate fractions, 
sample treatments with specific lyases were performed. Furthermore 
standard GAGs were run in a separate lane. 
As indicated in Figure 2, 0.45 M and 2 M LiCl fractions significantly 
differ in GAG composition: in the first eluate, in fact, only UTI is 
present, while free CS, together with Heparan Sulphate, are detectable in 
the 2 M LiCl fraction. 
 
 
Figure 2: Cellulose acetate electrophoresis. Lane 1 and 2 report the 
electrophoretic profile of 0.45 M and 2 M eluate fraction, respectively. UTI, 
Heparan Sulphate and Chondroitin Sulphate standards were loaded in lane 3. 
 
Differential elution of CS-containing UTI and free CS in urine was 
confirmed by means of SDS-PAGE analysis, as reported by Figure 3. In 
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the first two lanes, in fact, a well-defined band focuses at about 25 kDa 
corresponding to Chase ABC-treated UTI of a 0.45 M LiCl eluate 
fraction, whereas a smeared UTI band, due to the structural heterogeneity 
of the CS chain, is present at about 37 kDa of the second two lanes, 
corresponding to an untreated UTI fraction eluted with 0.45 M LiCl 
buffer. In the third and fourth couples of lanes either Chase-ABC treated 
or untreated 2 M eluted fraction, with no UTI are reported. 
 
 
Figure 3: SDS-PAGE electrophoretic profile evidencing differential elution 
patterns between 0.45 M and 2 M fractions. A well-defined band of Chase 
ABC-treated UTI focuses at about 25 kDa, while a smeared UTI band 
corresponding to the whole proteoglycan focuses at 37 kDa in the 0.45 M 
eluate fraction. No detectable bands of either intact or CS-depolymerised UTI 
are present in the 2 M eluate. 
 
A further validation of differential elution was carried out by FACE 
analysis of Chase-ABC treated fractions. As shown in Figure 4, the  
0.45 M fraction contains a low-sulphated CS, with a sulphation degree 
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ranging from 35 to 55 %, typical of UTI, whereas in the 2 M fraction a 
highly sulphated CS is present.  
 
Figure 4: FACE representative profiles of CS ∆-disaccharides derivatised with 
AMAC from 0.45 M (lanes 1-4) and 2 M (lanes 5-8) eluates. 
 
The method for UTI quantitation and structural characterization was 
applied to 29 patients affected by type 1 diabetes (age 31.76 ± 10.95), 22 
patients having type 2 diabetes (age 64.05 ± 7.40) and 42 healthy 
controls (age 38.00 ± 21.14), matched for age and sex with patients, 
evidencing higher levels of UTI in either type 1 or type 2 diabetic 
patients analysed. No differences between the two groups of patients 
were evidenced (P = 0.309) (Table 2) 
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Table 2: UTI levels (µg of UTI / mg creatinine), levels (µg UA / mg creatinine) 
and sulphation degree of UTI-bound chondroitin sulphate (expressed as 
percentage of ∆di-mono 4S / ∆di-mono 4S+∆di-non SCS) in controls, type 1 
and type 2 diabetic patients. 
 
 Gabriele Nieddu 
Identification and characterization of biomarkers in atherosclerosis and diabetes 
PhD thesis in International PhD school in Biomolecular and Biotechnological Sciences. 
Biochemistry, Physiology and Molecular Biology curriculum 
Università degli studi di Sassari 
25 
All diabetic patients were normoalbuminuric with an albumin excretion 
rate (AER) lower than 30 mg / 24 h except for 4 patients with type 2 
diabetes presenting with microalbuminuria (AER 52.2 mg / 24 h, 13.68 
µg UTI / mg creatinine; AER 81.9 mg / 24 h, 27.44 µg UTI / mg 
creatinine; AER 129.4 mg / 24 h, 22.71 µg UTI / mg creatinine; AER 
170 mg / 24 h, 22.94 µg UTI / mg creatinine). Differences between the 
group of patients with type 2 diabetes and controls still persisted even 
when microalbuminuric patients were not taken into account (P = 0.019) 
Spearman’s correlation tests between UTI levels and age, UTI levels and 
glycated haemoglobin, as well as UTI levels and microalbuminuria, were 
performed to rule out the possibility of an association between these 
parameters, evidencing no correlation (Table 3). 
 
UTI CS chains, from both diabetic patients and healthy controls, were 
quantified and structurally characterised by means of FACE analysis.  
More in detail, in order to quantify the different disaccharide species in 
the samples, a calibration curve was set up (y = 909.14x – 9891.9, R2 = 
0.9996) by resolving known quantities of ∆-disaccharides, ranging from 
25 to 800 ng as uronic acid (UA), as reported in Figure 5. ∆-
disaccharides were obtained from the depolymerisation of a purified UTI 
fraction. 
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Table 3: Spearman’s correlation tests between UTI levels and age, UTI levels 
and glycated haemoglobin, as well as UTI levels and microalbuminuria. 
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Figure 5: (A) Calibration curve obtained by image analysis of FACE profiles 
of increasing quantities (ranging from 25 to 800 ng of UA) of purified Chase-
ABC treated UTI. 
(B) ∆-disaccharides bands obtained by FACE analysis. Lane 1: mixture of 
commercial standard ∆-disaccharides (Δdi-nonSHA, Δdi-nonSCS, Δdi-mono 6S, 
Δdi-mono 4S, Δdi-mono 2S, Δdi-di (4,6)S, Δdi-di (2,4)S. OD: optical density. 
 
Levels and sulphation degree of CS chains were assessed by image 
analysis using Quantity One software (Bio-Rad laboratories). Total CS 
levels are significantly higher in type 1 and type 2 diabetes patients with 
respect to controls, being about 1.65 times greater (P = 0.037), but no 
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significant differences occur between type 2 diabetes patients and 
controls or between the two groups of patients (P = 0.087 and P = 0.791 
respectively). Moreover, sulphation degree of CS chains was lower in 
both classes of patients with respect to controls (P = 0.002 and P = 
0.018, respectively), as percentages of ∆di-mono 4S / ∆di-mono 4S+∆di-
non SCS were 37.709, 42.024 and 56.124, in type 1, type 2 diabetes 
patients and controls, respectively (Table 2). 
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5. DISCUSSION 
This study reports the structural characterization of both protein and 
chondroitin sulfate moieties of UTI in type 1 and type 2 diabetic patients 
as well as in healthy controls. UTI purification was performed by anion 
exchange chromatography starting from a volume of urine corresponding 
to 5 mg of creatinine and 0.45 M LiCl eluate fraction was splitted in two 
aliquots for structural and quantitative analyses. The first aliquot was 
subjected to Chase ABC treatment and the obtained disaccharide units 
were analysed by Fluorophore-Assisted Carbohydrate Electrophoresis 
following derivatization with 2-aminoacridone. The second one was 
resolved by SDS-PAGE. A calibration curve for protein quantitation was 
set up by using a highly purified UTI fraction.  
Furthermore, UTI band from several samples was subjected to trypsin 
digestion and structural characterization by Nano-LC-MS/MS analysis, 
allowing the identification of AMBP, which is a precursor proteolytically 
cleaved into the mature form of bikunin and α-1-microglobulin, with a 
high score and sequence coverage of 51%. 
The method was applied to urine samples from 29 patients with type 1 
diabetes, 22 patients with type 2 diabetes and 42 healthy controls, 
matched for age and sex with patients, evidencing higher UTI levels in 
both groups of patients (2.5 and 1.8 fold increase, respectively) with 
respect to controls (P < 0.0001 and P < 0.05, respectively). 
Analysis on GAG portion showed that total CS levels are significantly 
higher in type 1 diabetes patients with respect to controls, being about 
1.65 times greater (P = 0.037), whereas no significant differences occur 
between type 2 diabetes patients and controls or between the two groups 
of patients (P = 0.087 and P = 0.791 respectively). 
Sulphation degree of CS chains was lower in both groups of patients 
with respect to controls (P = 0.002 and P = 0.018, respectively), as 
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percentages of ∆di-mono 4S / ∆di-mono 4S+∆di-non SCS were 37.7%, 
42.0% and 56.1%, in type 1, type 2 diabetes patients and controls, 
respectively. 
Furthermore, the length of CS chain was evaluated as ratio between the 
moles of disaccharides and the moles of UTI (UTI molecular weight of 
15,974 Da, calculated by means of ExPASy Compute pI/Mw tool 
(http://www.expasy.org) according to the sequence reported by Xu et al. 
[61]). In this respect, no significant differences among the three classes 
of subjects considered were observed. 
 
Besides allowing UTI identification with a high score and good sequence 
coverage, MS analysis indicated the presence of several sites prone to 
oxidative modifications. Interestingly, one of them (residues 107-121) 
may represent a potential marker of oxidation in both type 1 and type 2 
diabetic patients. Preliminary results suggest that both UTI levels and 
structure could be modified, thus representing a useful marker of chronic 
inflammatory condition in type 1 and 2 diabetes. The effects of such 
quantitative and structural alterations on UTI localization, function and 
pathophysiological activities deserve further studies. 
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CHAPTER 2: Proteomic analysis of plasma-purified 
VLDL, LDL, and HDL fractions from atherosclerotic 
patients undergoing carotid endarterectomy: 




Cardiovascular disease (CVD) can affect heart or blood vessels, leading 
to coronary artery disease (angina and heart attack), heart failure, 
congenital heart disease, stroke, heart valve disease and cardiomyopathy. 
The most common risk factors for CVD are hypertension and 
atherosclerosis, this latter representing the leading cause of morbidity 
and mortality in industrialized countries, being related with about 50% of 
all deaths [62-64]. It is a chronic inflammation characterized by the 
accumulation of lipids and fibrous elements in medium and large arteries 
[65]. Several epidemiological studies over the past 50 years evidenced 
that atherosclerosis is related with both genetic and environmental risk 
factors. Genetic risk factors are principally hypertension, diabetes, 
obesity, elevated plasma levels of Low Density Lipoproteins (LDL) and 
Very-low Density Lipoproteins (VLDL), reduced levels of High Density 
Lipoproteins (HDL) and high levels of Lipoprotein (a), while 
environmental risk factors are mainly a high-fat diet, smoking, low 
antioxidant levels, lack of exercise and infectious agents [65, 66]. 
Furthermore, studies on mouse models revealed that there are dozens of 
genetic loci able to influence lipoprotein levels, body fat and other risk 
factors, and it is thought that over 4000 genes are implicated in the 
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pathogenesis of atherosclerosis, making this pathology a very complex 
phenomenon [63, 67]. 
The most relevant clinical complications of atherosclerosis are ascribed 
either to altered blood flow or to acute arterial occlusion, due to the 
formation of a thrombus or blood clot, which may occur as a 
consequence of plaque erosion or rupture and may result in myocardial 
infarction or stroke [65, 66]. 
According to the thesis formulated by Williams and Tabs in 1995, “The 
retention hypothesis”, the selective retention of apolipoprotein B-100 
containing lipoproteins by means of specific interactions with some extra 
cellular matrix components followed by oxidative modifications, 
represents the leading event in the development of atherosclerotic lesions 
[68]. 
Blood vessels sites that are more prone to develop an atheroma are 
regions of arterial branching or curvature, where flow is irregular and 
where endothelial cells are polygonal and with no particular orientation, 
contrary to tubular region where the blood flow is uniform and laminar 
and cells are ellipsoid and aligned with the flow [69]. 
LDL are entrapped into the extracellular matrix, where they are oxidized 
and become pro-inflammatory, triggering some significant consequences 
such as inhibition of nitric oxide (NO) production leading to vasodilation 
and subsequent diffusion of other LDL, that may result in the onset of an 
acute inflammatory state. Diabetic pathology may foster this 
inflammatory condition through the production of AGEs that interact 
with specific receptors on endothelial cells, resulting in decreased 
synthesis of NO and higher production and release of vasoconstrictor 
factors [70]. 
Consequently to oxidized-LDL stimulus, endothelial cells synthetize pro-
inflammatory molecules, cellular adhesion complexes (VCAM-1, 
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ICAM-1, P- and E-selectins), growth factors (macrophage-colony 
stimulating factor or M-CSF), pro-inflammatory cytokines and 
chemokines. In response to the secretion of these molecules, circulating 
monocytes and lymphocytes are attracted by chemotaxis to the 
inflammation site. As soon as monocytes differentiate into macrophages, 
together with endothelial cells (EC), produce reactive oxygen species 
(ROS), the enzymes sphingomyelinase (SMase), secretory phospholipase 
2 (sPLA2), myeloperoxidase (MPO) and other lipases that have an effect 
on oxidized LDL, which aggregate and become highly oxidized [65]. 
Aggregates of highly oxidized LDL are taken up by macrophages via 
scavenger receptor SR-A and CD36, whose expression is promoted by 
peroxisome proliferator-activated receptor-γ, a transcription factor whose 
ligands include oxidized fatty acids, or by cytokines such as tumour 
necrosis factor-α (TNF-α) and interferon-γ (IFN-γ). The accumulation of 
aggregates of highly oxidized LDL into the cytoplasm of macrophages 
leads to the formation of foam-cells [71], which cumulus in the sub-
endothelial space forms the earliest recognizable lesion, the fatty streak 
[72]. Cholesterol efflux promoted by macrophage-secreted 
apolipoprotein E, may inhibit the transformation of macrophages into 
foam cells, as demonstrated by studies on apo E-null mice [73]. 
 
Cytokines as Monocyte Chemoattractant Protein-1 (MCP-1), 
Interleuchin-8 (IL-8) and Interferon-γ (IFN-γ) as well as growth factors, 
stimulate Smooth Muscle Cells (SMCs) proliferation and migration from 
the tunica media into the intima, where produce and stimulate the 
synthesis of new extracellular matrix to form a collagenous fibrous cap, 
as a response to the inflammatory condition [74]. 
Dead macrophages, foam cells, extracellular debris and lipids accumulate 
in the necrotic core site and are enclosed by the fibrous cap leading to the 
 Gabriele Nieddu 
Identification and characterization of biomarkers in atherosclerosis and diabetes 
PhD thesis in International PhD school in Biomolecular and Biotechnological Sciences. 
Biochemistry, Physiology and Molecular Biology curriculum 
Università degli studi di Sassari 
34 
formation of the atheroma, the typical lesion of atherosclerosis. In case 
of persistent inflammatory stimulus, the response processes may 
continue, leading either to narrowing arterial lumen or to plaque erosion 
or rupture and subsequently to acute thrombotic vascular events such as 
myocardial infarction and stroke. The imbalance between synthesis of 
new extracellular matrix and proteolytic processes may lead to a friable 
and prone-to-rupture thin fibrous cap, which outcome is usually the 




Lipoproteins are supramolecular complexes, consisting of a hydrophobic 
core composed by triacylglycerols and cholesteryl esters and an 
amphipathic monolayer of phospholipids, cholesterol and proteins 
referred to as apolipoproteins. The latter can be either structural or 
exchangeable among different lipoprotein classes. Apolipoproteins and 
lipids combine together, resulting in three main classes of lipoprotein 
particles of different density and size. Actually, lipoproteins can be 
classified according to their density, from the lowest to the highest 
density, in chylomicrons (CM), very low density lipoproteins (VLDL), 
low density lipoproteins (LDL) and high density lipoproteins (HDL) 
[76]. Besides the stabilization of lipoprotein complexes, apolipoproteins 
also regulate lipoprotein interactions with cellular receptors and are 
involved in inflammatory and immune processes as well as in lipid 
metabolism by modulating enzymes implicated in these metabolic 
pathways [77]. 
CM are the biggest and least dense lipoproteins (d < 0.95 g/ml; diameter 
> 100 nm); they are synthesized by intestine and are absent in fasting 
subjects. CM core is principally composed by triacylglycerols, 
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containing some cholesteryl esters and minor fat-soluble substances like 
vitamins and carotenoids, and is stabilized with a surface monolayer of 
amphipathic molecules such as phospholipids, unesterified cholesterol 
and proteins. Apo B-48 is the main apolipoprotein of CM, however, as 
soon as they are secreted from enterocytes into plasma, they interact with 
other molecules and acquire other apolipoproteins, especially apo C-II, 
apo C-III and apo E. CM main function is to carry lipids of exogenous 
origin in several districts, such as liver, adipose tissue and skeletal 
muscle, where they are metabolized [78]. Apo C-II included in CM 
promotes the interaction between circulating CM and the enzyme 
lipoprotein lipase (LPL) anchored to the luminal side of the endothelial 
cells of extra-hepatic capillaries. LPL function is to hydrolyse the 
triacylglycerol core of CM, so that released non-esterified fatty acids can 
be either used as energy source or taken up by adipocytes and stored as 
triglycerides [79]. Remaining components of the chylomicron surface 
then dissociate and are acquired by other lipoproteins. The resulting 
particle, called chylomicron remnant, is removed from plasma by liver 
uptake through the interaction between apo E and lipoprotein receptor-
related protein (LRP) on the membrane of hepatocytes [78]. 
VLDL (d < 1.006 g/ml; 30 nm < diameter < 90 nm), triacylglycerol-rich 
lipoproteins, are the main neo-synthesized lipids transporters, from the 
liver to various tissues, mainly muscles and adipose tissues. In addition 
to triacylglycerols, VLDL contain free cholesterol and cholesterol esters.  
An additional class of lipoproteins, called intermediate density 
lipoprotein (IDL) (d = 1.006 – 1.019 g/ml), can be included between 
VLDL and LDL. IDL can be considered the resulting particles following 
VLDL disassembling [80] and their removal from the circulation is due 
to the interaction with LDL receptor (LDLR) located on hepatocytes. 
The remaining IDL portion is transformed into a LDL particle 
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consequently to a further reduction of the triacylglycerol component by 
hepatic lipase [81]. 
LDL particles (d = 1.019 – 1.063 g/ml; diameter ≈ 20 nm) are the end 
product of VLDL catabolism and represent the principal plasma carriers 
of cholesterol. Apo B-100 is the most abundant apolipoprotein in LDL, 
playing an important role in both lipoprotein structural stabilization and 
their removal from circulation [82]. Since LDL-receptor recognizes 
regions on apo B-100 as well as homologous regions on apo E, the 
receptor is also known as B/E receptor, and its mutations may cause 
impaired LDL uptake and subsequent elevation of their plasma levels, 
resulting in hypercholesterolemia [83]. Liver is the major site of plasma 
LDL uptake through B/E receptor, although LDL-receptor is expressed 
on the surface of most cells, as LDL represent the principal way to 
acquire cholesterol [76]. 
HDL, which are the smallest and the most dense lipoproteins (d = 1.063-
1.21 g/ml; diameter 10 nm), are responsible for the reverse transport of 
cholesterol in excess from different tissues to the liver and steroidogenic 
tissues for metabolic needs and excretion. Apo A-I, which accounts for 
nearly 90% of total protein content, takes part in HDL maturation, a 
process that involves the secretion of lipid-poor particles and 
extracellular lipid acquisition, mainly cholesterol and phospholipids [84]. 
LDL and HDL are the main plasma carriers of cholesterol, as they 
provide its mobilization from and to the liver. 
They play a key role in the development and in the progression of 
atherosclerotic lesions, as several studies reported that high levels of 
LDL and low levels of HDL strongly associate with the early events of 
atheroma development. More in detail, Apo B-100 is considered a strong 
predictor of cardiovascular risk, while Apo A-I is probably a protective 
factor [85]. 
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Lipoprotein (a) (Lp(a)) is another class of lipoproteins, with densities 
ranging between 1.05 and 1.09 g/ml, which strongly associate with 
higher cardiovascular risk, although the molecular mechanisms are still 
largely undetermined [86]. In Lp(a) a single disulphide bond between a 
heavily glycosylated multi-kringle protein called apolipoprotein(a) and 
an Apo B-100 of an LDL particle occurs [87]. 
 
1.3. APOLIPOPROTEINS 
The protein moiety of plasma lipoprotein consists of several 
apolipoproteins. Their main functions, besides supporting lipoprotein 
assembly and stabilizing their micellar structure, are the regulation of 
lipoprotein metabolism and the control of lipid transport and 
redistribution in various tissues. Moreover, lipoprotein particles 
maintenance and both recognition and interaction with cell surface 
lipoprotein receptors are determined by apolipoproteins [88]. 
The major apolipoproteins that constitute circulating lipoproteins can be 
classified either into exchangeable or non-exchangeable among different 
classes of lipoproteins. The non-exchangeable, called structural 
apolipoproteins, are mainly apo A-I and apo B-100, which account for 
nearly 90% of HDL and VLDL/LDL, respectively, while apo B-48 is the 
principal protein component of CM. Since their synthesis, these three 
apolipoproteins are assembled with lipids and they circulate bound to the 
same particle until they are removed from plasma. On the contrary, other 
apolipoproteins can move and exchange between lipoprotein particles 
and can bind other lipids in circulation [89].  
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2. AIM OF THE STUDY 
Lipoproteins are known to be implicated in both development and 
progression of atherosclerotic lesions. In fact, high levels of LDL 
concurrent with low HDL levels are strongly associated with an 
increased risk of atheroma formation. Several studies indicate that the 
protein moiety of lipoproteins may play a key role in the early events of 
atherosclerosis, because of their interaction with specific extracellular 
matrix components of medium and large arteries. Therefore, the 
characterization of apolipoproteins obtained by plasma lipoproteins 
isolated from atherosclerotic patients may be helpful in elucidating their 
roles in atherogenesis and in detecting plasma biomarkers that may be 
used as diagnostic for atherosclerosis, and may indicate the presence and 
stability of atheroma. Additionally, the identification of new biomarkers 
could contribute significantly to improve the therapeutic approaches used 
for the treatment of lipoprotein-associated disorders. 
The aim of this study was, hence, the characterization of apolipoprotein 
component of plasma lipoproteins isolated from patients undergoing 
carotid endarterectomy and the identification of differentially expressed 
apolipoproteins between patients and controls. To reach this objective, 
we analysed apolipoproteins from VLDL, LDL and HDL by means of 
two-dimensional electrophoresis (2-DE). 
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3. MATERIALS AND METHODS 
3.1. SAMPLE COLLECTION 
Plasma samples from both atherosclerotic patients and healthy controls 
were analysed for the characterization of apolipoproteins profiles in 
VLDL, LDL and HDL classes. 
Fasting blood samples were collected from 79 patients undergoing 
carotid endarterectomy and 57 healthy normolipemic controls in EDTA-
containing Vacutainer tubes and centrifuged at 2,000 x g for 10 minutes; 
obtained plasma was stored at -80 °C until analysis. Analyses were 
performed following random combination of equal amounts of plasma 
samples, leading to 4 homogeneous pools from patients and 4 from 
controls. 
All patients included in this study presented either a stenosis grade 
higher than 70% or a medium grade ulcerated lesion, as evidenced by 
echo-Doppler analysis, and were under pharmacological treatment for 
hypertension, dyslipidemia and/or diabetes. The main clinical parameters 
of both patients and controls are reported in Table 4. 
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Table 4: Clinical characteristics and lipid levels of patients and controls 
Parameters Patients (79) Controls (57) 
Age (years)  69.2 ± 7.2 62.5 ± 23.9 
Sex ratio, m/f  48/31 24/33 
Symptomatic, %  40.0 – 
Transient ischemic attack, %  28.6 – 
Ictus, % 71.4 – 
Diabetes, % 30.6 – 
Hypertension, %  87.8 – 
Dyslipidemic, %  83.7 – 
Triglycerides, mg/dL* 123.9 ± 53.2 86.6 ± 28.7 
Total cholesterol, mg/dL* 172.1 ± 43.4 175.7 ± 17.5 
LDL cholesterol, mg/dL* 97.4 ± 37.8 92.6 ± 32.1 
HDL cholesterol, mg/dL* 47.3 ± 13.4 50.1 ± 10.9 
*Values are mean ± SD 
  
 
3.2. LIPOPROTEIN PURIFICATION 
Lipoproteins were purified by isopycnic ultracentrifugation according to 
the methods described by Himber et al. [90] and McDowell et al. [91] , 
with slight modifications. Briefly, 3.9 mL of pooled plasma samples 
were added with 472.2 mg NaBr to d = 1.3 g/mL, put in centrifuge tubes 
(Beckman Coulter, Thin Wall Ultra-Clear, 14 mL, 14 x 95 mm) and 
overlaid with 8.1 mL of a 0.6% NaCl solution (d = 1.006 g/mL). The 
ultracentrifugation was carried out at 285,000 x g for 48 hours at 4 °C in 
an Optima L90 series ultracentrifuge equipped with a SW40 Ti rotor 
(Beckman Coulter). To avoid contamination, obtained lipoprotein 
fractions were further purified by a second ultracentrifugation step, 
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consisting of floating VLDL, LDL and HDL fractions in saline solutions 
at density 1.006, 1.063 and 1.21 g/mL respectively, under the same 
conditions as described above, for 24 hours. 
Following lipoprotein fractions recovery, desalting (final salt 
concentration < 5 mM) and concentration procedures were performed by 
means of Amicon Ultra-0.5 Centrifugal Filter Unit (10 KDa Molecular 
Weight Cut-Off, Millipore). Protein concentration was determined using 
DC Protein Assay Kit (Bio-Rad laboratories), according to the 
manufacturer’s instructions, using BSA as a standard. 
Aliquots of 500 μg (as protein) of LDL and 300 μg (as protein) of VLDL 
were delipidated by adding ice-cold tri-n-
butylphosphate:acetone:methanol (1:12:1), as reported by Mastro and 
Hall [92]. Precipitates were then subjected to repeated boiling and 
sonication passages in a buffer containing 10 mM TRIS, 4% CHAPS 
w/v, 1% DTT w/v, cooled to room temperature, and added with a 
solution containing 8M UREA, 4% CHAPS w/v, 1% DTT w/v, 0.4% 
carrier ampholytes v/v. 50 μg of non-delipidated HDL were treated as 
LDL and VLDL precipitates. After complete solubilisation, two-
dimensional electrophoresis analysis was carried out. 
 
3.3. 2-DE ANALYSIS 
Two-dimensional electrophoresis allows resolving proteins according to 
their isoelectric point (1st dimension) and, orthogonally, to their 
molecular weight (2nd dimension). 
Samples were applied to 70 mm IPG strips (pH 4–7, Bio-Rad 
laboratories), by overnight rehydration loading at 20°C, and, 
subsequently, isoelectrofocused at 50 μA/IPG strip for 22 kVh at 20°C. 
After focusing, proteins were in-gel reduced by incubating IPG strips 
with a 50 mM Tris buffer containing 6 M Urea, 30% glycerol v/v, 3% 
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SDS w/v, and 1% DTT w/v, followed by in-gel alkylation with the same 
solution containing 2.5% iodoacetamide w/v, in place of DTT, under 
continuous shaking for 15 minutes, prior to the second dimension. IPG 
strips were then sealed with 0.5% low melting point agarose w/v, in SDS 
running buffer, at the top of second dimension gels (8 cm x 7 cm x 0.1 
cm). SDS–PAGE was carried out, using 15% T, 3% C polyacrylamide 
gels, at 50V for 15 minutes and subsequently at 150V for about 90 
minutes. 
Gels were fixed in 30% ethanol v/v, 2% phosphoric acid v/v for 1hour, 
washed twice in 2% phosphoric acid v/v for 10 minutes, and then 
equilibrated in 18% ethanol v/v, 2% phosphoric acid v/v, 15% 
ammonium sulphate w/v for 30 minutes. The staining solution, 
containing 2% CBB G-250 (w/v), was then added to the same solution 
(final CBB concentration 0.02%). After 48 hours, gels were acquired by 
means of GS-800 calibrated densitometer (Bio-Rad laboratories) at 36.3 
µm resolution, and then analysed using PD-Quest 2-D analysis software, 
v 8.0.1 (Bio-Rad laboratories). Each spot was assigned a relative value 
corresponding to the single spot volume compared to the volume of all 
spots in gel, following background subtraction and normalization 
between gels. More in detail, in the normalization method adopted, the 
raw quantity of each spot in a member gel was divided by the total 
quantity of all spots in the gels included in the Master. 
 
3.4. IN-GEL DIGESTION AND MALDI-TOF MS 
ANALYSIS  
Spots of interest were excised from gels, minced and destained with a 
solution containing 2.5 mM NH4HCO3, 50% ACN (v/v) at 60 °C for 2 
hours, changing destaining solution three times. Gel fragments were 
dehydrated with pure ACN for 15 minutes, dried at room temperature 
 Gabriele Nieddu 
Identification and characterization of biomarkers in atherosclerosis and diabetes 
PhD thesis in International PhD school in Biomolecular and Biotechnological Sciences. 
Biochemistry, Physiology and Molecular Biology curriculum 
Università degli studi di Sassari 
43 
and then swollen with 5 mM NH4HCO3 solution, containing 10 ng/μl of 
trypsin, for 30 minutes on ice. Tryptic digestion was conducted overnight 
at 37°C. The resulting peptides were mixed with an equal volume of α-
cyano-4-hydroxycinnamic acid saturated solution (40% acetonitrile (v/v), 
0.1% trifluoroacetic acid (v/v)) and applied as a microcrystalline thin 
film onto a 96-spot MALDI target. Mass analyses were performed using 
a MALDI micro MX-Mass Spectrometer (Waters) according to the 
tuning procedures suggested by the manufacturer. Peak lists were 
generated using Protein Lynx Global Server v 2.2.5 (Waters) and 
searched against the Swiss-Prot human database (version 57.4) using 
Mascot (http://www.matrixscience.com). Research parameters included 
taxa (Homo sapiens), trypsin digestion, monoisotopic peptide masses, 
iodoacetamide modifications, one missed cleavage by trypsin, and a 
mass deviation of 50 ppm. Only protein identifications with significant 
Mascot scores (P < 0.05) were taken into consideration. 
 
3.5. WESTERN BLOTTING ANALYSIS 
Western blotting analyses on proteins resolved by SDS-PAGE were 
performed to compare the expression of exchangeable apolipoproteins 
between patients and controls. Following mono- or bi-dimensional 
electrophoresis, protein spots were electroblotted at 350 mA for 1 hour 
and 30 minutes onto PVDF membranes (GE Healthcare, UK). Then, 
membranes were incubated under continuous shaking with blocking 
solution (PBS-Tween-20 (0.1% Tween-20 in PBS) containing 3% non-
fat dry milk) for 1 hour at room temperature and then with the primary 
antibodies, diluted in the same blocking buffer, overnight at 4 °C. The 
primary antibodies used were the following: goat polyclonal anti-apo AI 
antibody (Millipore, AB740) diluted 1 : 8000, and mouse monoclonal 
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anti-SAA antibody (Abcam, Ab81483) diluted 1 : 1000 with blocking 
solution. 
After 30 minutes washing (PBS, 0.1% Tween-20), membranes were 
incubated for 1 hour at room temperature with (horseradish peroxidase) 
HRP-conjugated secondary antibodies diluted 1:5000 in blocking buffer 
solution (goat anti-mouse-HRP conjugate, Bio-Rad laboratories; rabbit 
anti-goat-HRP conjugate, Millipore). Following further membrane 
washing with PBS, 0.1% Tween-20 solution, proteins were revealed by 
enhanced chemiluminescence using Amersham ECL Prime Western 
Blotting Detection Reagent (GE Healthcare), by means of ChemiDoc 
XRS System (Bio-Rad laboratories). Densitometric analysis was 
performed using Quantity One 4.6.3 software (Bio-Rad laboratories). 
 
3.6. STATISTICAL ANALYSIS 
The comparison of exchangeable apolipoproteins expression in each 
purified lipoprotein fraction among atherosclerotic patients and healthy 
controls was performed by Student’s t-test for unpaired samples. The 
software package Sigma Stat 3 (Systat Software) was used for statistical 
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4. RESULTS 
2-DE coupled with MS was applied to plasma VLDL, LDL and HDL 
apolipoproteins obtained from both patients undergoing carotid 
endarterectomy and healthy normolipemic subjects. Patients included in 
the present study were selected for surgery having either a high-grade 
stenosis (> 70%) or an ulcerated lesion, as diagnosed by means of echo-
Doppler analysis. 
As apo B-100 accounts for about 95% of the total protein moiety of 
VLDL and LDL, large amounts of these lipoproteins were processed in 
order to allow the detection and identification of less abundant 
apolipoproteins. Furthermore, due to the high lipid/protein ratio in both 
VLDL and LDL, a delipidation step was mandatory. 
Through the adopted fractionation procedure, consisting in an isopycnic 
gradient ultracentrifugation followed by an additional washing step, we 
were able to obtain highly purified lipoprotein fractions. No albumin or 
other plasma proteins were in fact detected in CBB G-250 stained 2-DE 
gels. Moreover, western blotting analysis on HDL fraction did not reveal 
any apo B-100 contamination. 
By means of this approach combined with peptide mass fingerprinting, 
we were able to identify 2 isoforms of apo J, 2 isoforms of apo A-IV, 5 
isoforms of apo E, 6 isoforms of apo A-I, 3 isoforms of apo D, 2 
isoforms of acute phase serum amyloid A protein (AP-SAA), 1 isoform 
of apo C-II and 2 isoforms of apo C-III, in both VLDL and LDL 
fractions. Apo B-100 was not detectable in any VLDL or LDL 2-DE 
maps because of its high molecular weight and hydrophobicity. 
3 isoforms of apo E, 6 of apo A-I, 3 of apo D, 2 of AP-SAA, 1 of apo C-
II, and 2 of apo C-III were identified in HDL fraction 
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Representative 2-DE maps from VLDL, LDL and HDL fractions and 
from the corresponding plasma sample are reported in Figure 6. 
 
Figure 6: Representative 2-DE maps reporting protein expression patterns of 
VLDL (A), LDL (B), HDL (C) fractions, and corresponding plasma sample 
(D). Protein spots identified by MALDI-TOF MS analysis are indicated. 
 
Following apolipoprotein separation and identification, differential 
apolipoproteins expression analysis was performed on VLDL, LDL and 
HDL. No differences were observed in the relative abundance of all 
apolipoprotein with the exception of AP-SAA, which expression was 
2.3, 14 and 1.5 times higher in VLDL, LDL, and HDL fractions, 
respectively, in patients with respect to controls (𝑃 = 0.001, 𝑃 = 0.003, 
and 𝑃 = 0.045), as shown in Figure 7. 
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Figure 7: Relative amount of AP-SAA in VLDL, LDL and HDL fractions. AP-
SAA levels, expressed as relative abundance, differ significantly between 
patients and controls in all lipoprotein classes analysed. Data were obtained 
by image analysis on 2-DE maps using PD-Quest software and are expressed 
as mean ± SD. 
 
Figure 8 shows AP-SAA differential expression, confirmed on each 
lipoprotein fraction using apo A-I levels for data normalization by 
western blotting analysis (𝑃 = 0.03, 𝑃 = 0.03, and 𝑃 = 0.05, for VLDL, 
LDL, and HDL fractions, respectively). 
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Figure 8: One-dimensional western blotting analysis reporting AP-SAA and 
apo A-I expression in VLDL, LDL and HDL fractions obtained from 4 pooled 
plasma samples from patients with advanced atherosclerotic lesion (lanes 1-4) 
and 4 pooled plasma samples from normolipemic controls (lanes 5-8). 
Apo A-I levels were used for data normalization. 
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5. DISCUSSION 
Apolipoproteins play key roles in lipoprotein functions, as they are 
involved in several metabolic pathways, such as recognition by specific 
receptors on cell surfaces or regulation of the activity of various enzymes 
[77]. Further information about apolipoprotein composition may 
contribute to revealing their role in atherogenesis. 
Up to now, no studies have been carried out on differential 
apolipoprotein expression in atherosclerotic patients undergoing carotid 
endarterectomy compared to healthy controls. The major limitation of the 
present study is that it was conducted on randomly combined pooled 
plasma samples and, therefore, data reported represent an average value 
from 15 to 20 samples. Moreover, a measure of how much variation or 
dispersion from the average exists is not reported. Despite that, this study 
provides the comparison of exchangeable apolipoproteins levels in each 
lipoprotein fraction from a noteworthy number of patients and controls. 
Indeed, these preliminary results may represent a useful starting point for 
further, more specific analyses that could be carried out on each sample 
separately (e.g., ELISA on plasma samples and plaque extracts, and 
immunohistochemistry on endarterectomy specimens). 
By 2-DE coupled with MS we were able to identify 23 different 
apolipoprotein isoforms from lipoproteins obtained from both 
atherosclerotic patients and controls. The method adopted, due to its high 
resolution and sensitivity, allowed the identification of AP-SAA as a 
potential marker of advanced carotid atherosclerosis lesions, as its levels 
were higher in all lipoprotein fractions, increasing up to fourteen-fold in 
atherosclerotic patients LDL fraction. This evidence was confirmed by 
western blotting analysis on each lipoprotein fraction. 
Serum amyloid A protein is an acute-phase protein, synthesized 
primarily in the liver, that circulates mainly associated to HDL. During 
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an acute-phase reaction, plasma levels of AP-SAA may increase up to 
1000-fold, as its synthesis is upregulated by either inflammatory 
cytokines or peptide hormone signals [93]. 
Besides some evidences of an antiatherogenic role in promoting 
cholesterol efflux from cells [94, 95], SAA was proven to potentiate 
prothrombotic events by inducing tissue factor expression [96], as well 
as to have proatherogenic effects, such as promotion of monocytes and 
neutrophils chemotaxis [97, 98], macrophage foam cells formation [99], 
stimulation of proinflammatory cytokines secretion by monocytes, 
macrophages and lymphocytes [100-102], and induction of endothelial 
dysfunction [103, 104]. 
Moreover, as a proteoglycan-binding domain on SAA carboxy-terminal 
region has been identified [105] and as this acute-phase protein could 
stimulate the synthesis of vascular proteoglycans with an increased LDL-
binding affinity [106], a role for SAA in lipoprotein subendothelial 
retention has been suggested. Furthermore, these findings are consistent 
with a study reporting that SAA highly correlates with lesion area, apo 
A-I area, apo B-100 area, and perlecan area, being deposited at all stages 
of lesion development in murine atherosclerosis [107]. 
Additionally, earlier studies reported the presence of both acute phase 
and constitutive SAA in atherosclerotic lesions [108], as well as of its 
mRNA in several cell types of human coronary and carotid arteries 
atherosclerotic lesions [109]. Noteworthy, elevated SAA levels strongly 
correlate with coronary artery disease [110]. 
Moreover, SAA-LDL association was reported to reflect intravascular 
inflammation directly suggesting this complex as a new prognostic 
marker in stable coronary artery disease [111]. Finally, a strong 
independent relationship between SAA and future cardiovascular events 
was demonstrated [112]. 
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Our results further corroborate previous hypotheses reporting AP-SAA 
as a potential marker for advanced atherosclerotic lesions, suggesting a 
direct role for SAA in atheroma development. Finally, we hypothesize a 
role for LDL as AP-SAA carrier into the artery wall, where it could exert 
its noxious effects. 
 
The results of this study have been recently published in an international 
scientific journal [113]. 
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